Silexion Therapeutics Corp 8K

Silexion Therapeutics announced Q2 2026 results, the advancement of SIL204 into a Phase 2/3 trial, supportive preclinical data, and multiple financing and capital-structure moves to support the program and maintain Nasdaq listing compliance.

On August 14, 2026, Silexion Therapeutics Corp. reported its second quarter and year-to-date 2026 financial results and provided a business update, highlighting the transition of its lead siRNA candidate SIL204 into an active Phase 2/3 clinical program for locally advanced pancreatic cancer in Israel and Germany (including CTA approval from Germany’s BfArM and trial initiation at Tel Aviv Sourasky Medical Center on July 29, 2026), new preclinical immuno-oncology data supporting a coordinated immune‑sensitization profile across multiple KRAS mutations, and a series of capital-structure and financing actions—such as a 1-for-10 reverse share split, warrant inducements, ATM share sales, partial conversions of a related party promissory note, and an August 13, 2026 registered public offering raising approximately $2.5 million in gross proceeds—intended to fund clinical execution and restore compliance with Nasdaq’s shareholders’ equity listing requirement, while also disclosing increased R&D and G&A expenses, a larger net loss, and a materially lower cash balance as of June 30, 2026.

Filing Facts

CIK

2022416

Ticker

-

Form

8K

Source Type

sec

Accession

0001178913-26-004136

Alert Tier

7